Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMMLDG8)

Drug Name
Anatumomab mafenatox Drug Info
Synonyms ABR-214936; Fab5T4V13-SEAm9; PNU-214936; TTS-CD2; CD-2, Active Biotech
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Terminated [1]
Cross-matching ID
TTD Drug ID
DMMLDG8

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Oncotrophoblast glycoprotein 5T4 (TPBG) TT70MLA TPBG_HUMAN Not Available [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Oncotrophoblast glycoprotein 5T4 (TPBG) DTT TPBG 5.278 7.52 7.518 7.012
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Breast cancer
ICD Disease Classification 2C60-2C65
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Oncotrophoblast glycoprotein 5T4 (TPBG) DTT TPBG 1.30E-01 0.15 0.17
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer. 2007 Feb 26;96(4):567-74.